### FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

	Washington	i, D.C. 20549	
<b>STATEMENT</b>	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

	OMB APPROVAL									
	OMB Number:	3235-028								
- 1	Fatimated average I									

37 hours per response: 0.5

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or S	Section	30(h)	of the	Investm	nent C	ompany Act	of 1940							
1. Name and Address of Reporting Person* <u>Bronfein Michael G</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol BioScrip, Inc. [ BIOS ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
												X	Direc	ctor		10% C	wner		
(Last)	t) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 09/15/2017									Offic belov	cer (give title ow)		Other (specify below)	
1600 BROADWAY, SUITE 950					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)														X	Forn	n filed by One	e Report	ing Pers	on
DENVER CO 80202												Form filed by More than One Reporting Person							
(City)	(St	ate) (	Zip)																
		Tabl	e I - N	on-Deriv	/ative	Sec	uritie	s Ac	quire	d, Di	sposed o	f, or E	Benefic	ially	Owne	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/				Execution Date,		oate,	3. Transaction Code (Instr. 8)  4. Securities Acquired (A) (Disposed Of (D) (Instr. 3, 4)				and 5) Secur Benef Owne		icially d Following	6. Own Form: I (D) or I (I) (Inst	Direct ndirect	7. Nature of Indirect Beneficial Ownership			
								Code V Amount		(A) or (D)	Price	Price		Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
Common Stock, \$.0001 Par Value 09/15/20				2017	017		S		27,000	D \$2.693		938(1)	8(1) 129,669		I	)			
		Та	ble II								osed of, convertib				vned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable Expiration Date (Month/Day/Year)		ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		Deri Seci (Inst		derivative Securities	Owne Form: Direct or Ind (I) (Ins	nership m: ect (D) ndirect Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				•	Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amount or Number of Shares						

#### **Explanation of Responses:**

1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions in prices ranging from \$2.68 to \$2.71, inclusive. The reporting person undertakes to provide BioScrip, Inc., any security holder of BioScrip, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

/s/ Michael G. Bronfein

09/19/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.